10X Genomics, Inc., a prominent player in the life sciences and diagnostics sector, recently disclosed its financial results for the second quarter of 2026. The company, headquartered in Pleasanton, United States, specializes in developing software for analyzing complex biological systems, including genetic and immune cells. It serves a global customer base through its online platform and is listed on the Nasdaq stock exchange.
In its latest financial update, 10X Genomics reported a modest revenue increase compared to the same period in 2025, excluding one-off settlement items. This growth reflects the company’s ongoing efforts to expand its market presence and enhance its product offerings. The gross margin saw a notable improvement, rising by approximately three percentage points from the previous year. This improvement was primarily attributed to reduced manufacturing costs and tariff refunds, which positively impacted the company’s profitability.
Despite the revenue growth, 10X Genomics experienced an increase in operating expenses, largely due to a reduced settlement gain. However, when these settlement effects are excluded, operating expenses remained broadly flat. The quarter concluded with both an operating loss and a net loss, underscoring the challenges the company faces in achieving profitability. Nonetheless, the company’s financial position remains robust, with cash and marketable securities exceeding $550 million.
Looking ahead, 10X Genomics has raised its full-year revenue outlook, projecting figures slightly above its previous guidance. This optimistic revision is driven by sustained customer demand and the establishment of new collaborations with major research institutions. These partnerships are expected to bolster the company’s research capabilities and expand its influence in the life sciences sector.
As of August 6, 2026, the company’s stock closed at $52.03, with a 52-week high of $52.22 and a low of $11.16 recorded on October 13, 2025. The market capitalization stands at approximately $6.78 billion. Despite a negative price-to-earnings ratio of -77.5, reflecting the current lack of profitability, 10X Genomics continues to focus on strategic growth initiatives to enhance its market position and financial performance in the long term.
